Mylan Launches Generic Version of Epivir® Film Coated Tablets in the UK and Italy, its First Generic ARV Launch in Europe

 Mylan Launches Generic Version of Epivir® Film Coated Tablets in the UK and
                Italy, its First Generic ARV Launch in Europe

  PR Newswire

  PITTSBURGH, POTTERS BAR, England, and MILAN, June 6, 2012

PITTSBURGH,POTTERS BAR, England, and MILAN, June 6, 2012 /PRNewswire/
--Mylan Inc. (Nasdaq: MYL) today announced that its UK and Italy-based
subsidiaries have launched Lamivudine Film Coated Tablets, 150 mg and 300 mg.
This product is the generic version of GlaxoSmithKline's Epivir® Tablets,
indicated as part of antiretroviral (ARV) combination therapy for the
treatment of HIV-infected adults and children. This is the first generic HIV
treatment to be available from Mylan in Europe.

Mylan CEO Heather Bresch commented: "As one of the world's leading providers
of affordable ARVs, Mylan has a long history of contributing to the fight
against HIV/AIDS across the developing world. We are excited that we can now
bring our passion and experience in this important area to the European
markets with the launch of Lamivudine, further delivering on our commitment to
providing high quality and affordable medicines to patients around the world."

Didier Barret, Mylan's EMEA President, added: "We are very proud to launch our
first ARV treatment in the European market, starting with hospitals in the UK
and Italy. Our strong corporate commitment and expertise in the HIV space will
support our continued development of a full HIV treatment portfolio in
Europe."

Lamivudine Tablets had sales of approximately 3.4 million euros (2.6 million
pounds Sterling) in the UK and sales of approximately 12.5 million euros in
Italy for the 12 months ending March 31, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

Website: http://www.mylan.com
Contact: Nina Devlin (media), +1-724-514-1968, or Laetitia Tonel (Media EMEA),
+33-4-37-25-77-06, or Kris King (Investors), +1-724-514-1813
 
Press spacebar to pause and continue. Press esc to stop.